Literature DB >> 24155115

Optical coherence tomography derived differences of plaque characteristics in coronary culprit lesions between type 2 diabetic patients with and without acute coronary syndrome.

Sebastian Reith1, Simone Battermann, Rainer Hoffmann, Nikolaus Marx, Mathias Burgmaier.   

Abstract

OBJECTIVE: To compare optical coherence tomography (OCT)-derived plaque characteristics of coronary target lesions between diabetic patients with acute coronary syndrome (ACS) versus stable angina pectoris (SAP).
BACKGROUND: In vivo assessment of plaque composition of coronary culprit lesions in a cardiovascular high-risk population with diabetes mellitus is incompletely elucidated.
METHODS: 102 diabetic patients with coronary de novo lesions were enrolled and categorized into an ACS-group (40 patients) and a SAP-group (62 patients) according to their clinical presentation. Assessment of clinical data, angiographic, and OCT imaging including the analysis of plaque composition and lipid content of the target lesions were performed prior to percutaneous coronary intervention and compared between the two groups.
RESULTS: Plaque characteristics of patients in the ACS-group compared with the SAP-group showed a higher incidence of lipid-rich plaque [33 (82.5%) vs. 25 (40.3%)], thin-capped fibroatheroma [29 (72.5%) vs. 10 (16.1%)], macrophage infiltration [32 (80.0%) vs. 21 (33.9%)], thrombus [23 (57.5%) vs. 2 (3.2%)], and plaque rupture [27 (67.5%) vs. 2 (3.2%)] (all P < 0.001). Moreover, there was a wider lipid arc (174.5 ± 33.8° vs. 122.9 ± 43.9°), a longer lipid plaque length (6.52 ± 2.04 mm vs. 3.73 ± 2.16 mm), a greater lipid volume index (1117.2 ± 349.9 vs. 504.8 ± 379.3), and a smaller minimal fibrous cap thickness (51.52 ± 9.14 µm vs. 80.33 ± 26.71 µm) within lipid-rich lesions of ACS patients (all P < 0.001).
CONCLUSION: Diabetic patients with ACS exhibit more vulnerable plaque features in coronary culprit lesions compared with diabetic patients with SAP. This may provide rationale for a specific therapeutic strategy either by pharmacological plaque stabilization or coronary intervention in any lesion with vulnerable plaque morphology in patients with diabetes.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  fibrous cap thickness; lipid-rich plaque; vulnerable plaque

Mesh:

Year:  2013        PMID: 24155115     DOI: 10.1002/ccd.25267

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  11 in total

Review 1.  Vascular imaging in diabetes.

Authors:  K Levitt; L Vivas; B Courtney; K A Connelly
Journal:  Curr Atheroscler Rep       Date:  2014-04       Impact factor: 5.113

2.  Combined optical coherence tomography morphologic and fractional flow reserve hemodynamic assessment of non- culprit lesions to better predict adverse event outcomes in diabetes mellitus patients: COMBINE (OCT-FFR) prospective study. Rationale and design.

Authors:  Mark W Kennedy; Enrico Fabris; Alexander J Ijsselmuiden; Holger Nef; Sebastian Reith; Javier Escaned; Fernando Alfonso; Niels van Royen; Wojtek Wojakowski; Adam Witkowski; Ciro Indolfi; Jan Paul Ottervanger; Harry Suryapranata; Elvin Kedhi
Journal:  Cardiovasc Diabetol       Date:  2016-10-10       Impact factor: 9.951

3.  Morphological features of coronary plaques in WHHLMI rabbits (Oryctolagus cuniculus), an animal model for familial hypercholesterolemia.

Authors:  Satoshi Yamada; Tomonari Koike; Takayuki Nakagawa; Nobue Kuniyoshi; Yu Ying; Hiroyuki Itabe; Atsushi Yamashita; Yuji Asada; Masashi Shiomi
Journal:  Exp Anim       Date:  2016-12-27

4.  A score to quantify coronary plaque vulnerability in high-risk patients with type 2 diabetes: an optical coherence tomography study.

Authors:  Mathias Burgmaier; Martin Hellmich; Nikolaus Marx; Sebastian Reith
Journal:  Cardiovasc Diabetol       Date:  2014-08-21       Impact factor: 9.951

5.  Mechanical properties of the everolimus-eluting bioresorbable vascular scaffold compared to the metallic everolimus-eluting stent.

Authors:  Daniel Dalos; Clemens Gangl; Christian Roth; Lisa Krenn; Sabine Scherzer; Markus Vertesich; Irene Lang; Gerald Maurer; Thomas Neunteufl; Rudolf Berger; Georg Delle-Karth
Journal:  BMC Cardiovasc Disord       Date:  2016-05-25       Impact factor: 2.298

6.  Type 2 diabetes mellitus is associated with a lower fibrous cap thickness but has no impact on calcification morphology: an intracoronary optical coherence tomography study.

Authors:  Andrea Milzi; Mathias Burgmaier; Kathrin Burgmaier; Martin Hellmich; Nikolaus Marx; Sebastian Reith
Journal:  Cardiovasc Diabetol       Date:  2017-12-01       Impact factor: 9.951

7.  Non-culprit plaque characteristics in acute coronary syndrome patients with raised hemoglobinA1c: an intravascular optical coherence tomography study.

Authors:  Shaotao Zhang; Jiannan Dai; Haibo Jia; Sining Hu; Hongwei Du; Ning Li; Yongpeng Zou; Yanan Zou; Shenhong Jing; Yan Wang; Rong Sun; Bo Yu
Journal:  Cardiovasc Diabetol       Date:  2018-06-15       Impact factor: 9.951

8.  Difference in plaque characteristics of coronary culprit lesions in a cohort of Egyptian patients presented with acute coronary syndrome and stable coronary artery disease: An optical coherence tomography study.

Authors:  Amr ElFaramawy; Mina Youssef; Mohamed Abdel Ghany; Khaled Shokry
Journal:  Egypt Heart J       Date:  2017-12-27

9.  Macrophage accumulation within coronary arterial wall in diabetic patients with acute coronary syndrome: a study with in-vivo intravascular imaging modalities.

Authors:  Takaaki Kogo; Takafumi Hiro; Daisuke Kitano; Tadateru Takayama; Daisuke Fukamachi; Tomoyuki Morikawa; Mitsumasa Sudo; Yasuo Okumura
Journal:  Cardiovasc Diabetol       Date:  2020-09-05       Impact factor: 9.951

10.  High cardiovascular risk of patients with type 2 diabetes is only partially attributed to angiographic burden of atherosclerosis.

Authors:  Simone Battermann; Andrea Milzi; Rosalia Dettori; Kathrin Burgmaier; Nikolaus Marx; Mathias Burgmaier; Sebastian Reith
Journal:  Diab Vasc Dis Res       Date:  2020 Sep-Oct       Impact factor: 3.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.